145 related articles for article (PubMed ID: 36962423)
21. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
[TBL] [Abstract][Full Text] [Related]
22. The potential cost-effectiveness of HPV vaccination among girls in Mongolia.
Luvsan ME; Vodicka E; Jugder U; Tudev U; Clark A; Groman D; Otgonbayar D; Demberelsuren S; LaMongtagne DS; Pecenka C
Vaccine X; 2022 Aug; 11():100161. PubMed ID: 35509519
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of dengue vaccination in ten endemic countries.
Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
[TBL] [Abstract][Full Text] [Related]
24. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
[TBL] [Abstract][Full Text] [Related]
25. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries.
Obeng-Kusi M; Habila MA; Roe DJ; Erstad B; Abraham I
J Med Econ; 2021 Nov; 24(sup1):1-13. PubMed ID: 34866541
[TBL] [Abstract][Full Text] [Related]
29. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
[TBL] [Abstract][Full Text] [Related]
30. Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: A modelling study.
You T; Zhao X; Hu S; Gao M; Liu Y; Zhang Y; Qiao Y; Jit M; Zhao F
EClinicalMedicine; 2023 Feb; 56():101789. PubMed ID: 36618898
[TBL] [Abstract][Full Text] [Related]
31. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay.
Constenla DO
Rev Panam Salud Publica; 2008 Aug; 24(2):101-12. PubMed ID: 19062601
[TBL] [Abstract][Full Text] [Related]
32. Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries.
Marseille E; Jiwani A; Raut A; Verguet S; Walson J; Kahn JG
BMJ Open; 2014 Jun; 4(6):e003987. PubMed ID: 24969782
[TBL] [Abstract][Full Text] [Related]
33. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
[TBL] [Abstract][Full Text] [Related]
34. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India.
Gupta M; Prinja S; Kumar R; Kaur M
Health Policy Plan; 2013 Jan; 28(1):51-61. PubMed ID: 22407018
[TBL] [Abstract][Full Text] [Related]
36. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
38. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
39. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]